A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis

ClinicalTrials.gov ID: NCT00160602

Public ClinicalTrials.gov record NCT00160602. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III Multi-center, Double-blind, Placebo-controlled, Parallel Group 24-Week Study to Assess the Efficacy and Safety of Two Dose Regimens of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A 24 week study in which patients are given study medication and assessed for signs and symptoms of rheumatoid arthritis. X-rays are performed to assess the progress of joint damage during the study.

Study identification

NCT ID: NCT00160602
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: UCB Pharma; Industry
Enrollment: 590 participants

Conditions and interventions

Conditions

Rheumatoid Arthritis

Interventions

Certolizumab Pegol Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 2005 (Type not available)
Primary completion: Sep 2006 (Actual)
Completion: Sep 2006 (Actual)
Last update posted: Dec 1, 2020

2005 – 2006

United States locations

U.S. sites: 17
U.S. states: 11
U.S. cities: 17

Facility	City	State	ZIP	Site status
Not listed	Montgomery	Alabama	—	—
Not listed	Sun City West	Arizona	—	—
Not listed	Palm Desert	California	—	—
Not listed	Pasadena	California	—	—
Not listed	Santa Maria	California	—	—
Not listed	Naples	Florida	—	—
Not listed	Palm Harbor	Florida	—	—
Not listed	South Miami	Florida	—	—
Not listed	New Orleans	Louisiana	—	—
Not listed	St Louis	Missouri	—	—
Not listed	New Brunswick	New Jersey	—	—
Not listed	Stratford	New Jersey	—	—
Not listed	New York	New York	—	—
Not listed	Rochester	New York	—	—
Not listed	Canfield	Ohio	—	—
Not listed	Wynnewood	Pennsylvania	—	—
Not listed	San Antonio	Texas	—	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 53 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00160602, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 1, 2020 · Synced Oct 21, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00160602 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →